0.41
+0.92%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Heartbeam
From its filings with the US Securities and Exchange Commission
Heartbeam is based in Santa Clara, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BEAT. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported a net loss of $21.0m. At that date it held total assets of $5.8m and shareholders' equity of $2.6m.
HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (“ECG”) solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart’s electrical activity from three dimensions and synthesize a 12-Lead (“12L”) ECG from these signals.
We believe our Products (“Products” or “Product”) and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payers, and will also address the rapidly growing field of ambulatory cardiac monitoring. As part of our long-term vision, we believe that we are uniquely positioned to play a central role in high-risk Coronary Artery Disease (“CAD”) monitoring, given positive, proof-of-concept data from the initial feasibility studies that demonstrated comparable performance of the HeartBeam System and the standard 12L ECG in ischemia detection. CAD patients are at increased risk for a heart attack or Myocardial Infarction (“MI”). Additionally, our unique portable form-factor will make high-fidelity insights easily accessible, wherever patients are, compared to a standard 12L ECG, which is typically limited to a healthcare setting.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Oct 2021
- Employees
- 15
- Website
- heartbeam.com ↗
Leadership
Pay as last reported
- Mr. Richard FerrariExecutive Chairman of the Board and Independent Director, since 2019$245,000
- Dr. Branislav VajdicPresident, Founder, Director, since 2024$626,804
- Mr. Robert EnoChief Executive Officer, Director, since 2023$490,675
- Mr. Timothy CruickshankChief Financial Officer$976,363
- Mr. Kenneth PersenChief System Deployment Officer$371,776
- Mr. George de UriosteIndependent Director$150,000
- Mr. Willem ElfrinkIndependent Director, since 2021$150,000
- Dr. Michael JaffIndependent Director$131,071
- Mr. Kenneth NelsonIndependent Director$127,775
- Ms. Marga Ortigas-WedekindIndependent Director$140,000
- Mr. Mark StromeIndependent Director$135,000
- Mr. Chris TysonExecutive Vice President - MZ North America
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Proprietary Vector Electrocardiography technology enables three-dimensional cardiac electrical activity imaging.
- Two patented products, HeartBeam AIMI and HeartBeam AIMIGo, are in development.
- High resolution ambulatory ECG solutions detect cardiac disease inside facilities.
Weaknesses
- The company is a development stage firm with only fifteen employees.
- Operations are limited to Santa Clara, California, with a small team.
- Commercialization of cardiovascular diagnostic technology is not yet fully realized.
Opportunities
- Remote heart attack detection via HeartBeam AIMIGo facilitates outside facility monitoring.
- Cloud-based diagnostic software systems support the credit card-sized ECG device.
- Acute care settings benefit from 3D baseline and symptomatic ECG comparisons.
Threats
- Development stage status implies potential delays in commercializing patented technologies.
- Small employee count of fifteen may limit rapid market expansion.
- Reliance on smartphone apps introduces potential connectivity or compatibility challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.